Michael Hahn

USPTO Granted Patents = 42 (Patent Applications = 29)

CIPO Patents = 7 (Patent Applications = 18)

EPO Patents = 28 (Patent Applications = 47)

Average Co-Inventor Count = 8.2

ph-index = 8

Forward Citations = 208(Granted Patents)

Location History:

Krailing, DE (2017)
Langenfeld, DE (2005 - 2022)
Krailling, DE (2016 - 2023)

Company Filing History:

15 out of 378

Bayer Pharma Aktiengesellschaft

patents

12 out of 721

Bayer Intellectual Property Gmbh

patents

8 out of 12,157

Bayer Aktiengesellschaft

Bayer Schering Pharma Ag

Bayer Schering Pharma Aktiengellschaft

Meiji Seika Pharma Co., Ltd.

patents

where one patent can have more than one assignee

Years Active: 2005-2024

where 'Filed Patents' based on already Granted Patents

42 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12180227 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2024-12-31),

2. 12138256 - Treatment of cardiopulmonary disorders (2024-11-12),

3. 11707758 - Aerosol generator (2023-07-25),

4. 11610473 - Control device for aerosol nebulizer system (2023-03-21),

5. 11377417 - Branched 3-phenylpropionic acid derivatives and their use (2022-07-05),

6. 11208422 - Substituted bridged diazepane derivatives and use thereof as TASK-1 and TASK-3 inhibitors (2021-12-28),

7. 11154896 - Aerosol generator (2021-10-26),

8. 11098063 - Diazabicyclic substituted imidazopyrimidines and their use for the treatment of breathing disorders (2021-08-24),

9. 10759794 - 2-phenyl-3-(piperazinomethyl)imidazo[1,2-A]pyridine derivatives as blockers of task-1 and task-2 channels, for the treatment of sleep-related breathing disorders (2020-09-01),

10. 10414765 - Substituted perhydropyrrolo[3,4-c]pyrrole derivatives and the use of same (2019-09-17),

11. 10265314 - SGC stimulators in combination with additional treatment for the therapy of cystic fibrosis (2019-04-23),

12. 10259776 - Branched 3-phenylpropionic acid derivatives and their use (2019-04-16),

13. 10189856 - Use of sGC stimulators, sGC activators, alone and combinations with PDE5 inhibitors for the treatment of systemic sclerosis (SSc) (2019-01-29),

14. 10053428 - 5-aminotetrahydroquinoline-2-carboxylic acids and their use (2018-08-21),

15. 10023528 - Branched 3-phenylpropionic acid derivatives and their use (2018-07-17),

Title: Innovative Contributions of Michael Hahn in Breathing and Cardiopulmonary Disorder Treatments

Introduction: Michael Hahn, based in Langenfeld, Germany, is a prolific inventor with an impressive portfolio of 36 patents. His expertise lies primarily in the development of novel pharmaceutical compounds aimed at treating various respiratory and cardiopulmonary conditions. His latest innovations showcase significant advancements in medical therapies.

Latest Patents: Michael Hahn has made notable contributions through his recent patents. One of his latest inventions is focused on *diazabicyclic substituted imidazopyrimidines* aimed at treating breathing disorders. This patent details the use of these innovative compounds for the treatment and prevention of diseases related to breathing, including sleep-related disorders like obstructive sleep apnea and snoring.

Another significant patent addresses the treatment of cardiopulmonary disorders. It involves a specific compound designed for inhalative treatment modalities for conditions such as pulmonary arterial hypertension and chronic obstructive pulmonary disease. The patented methods emphasize the dosage forms and the administration process crucial for effective treatment.

Career Highlights: Throughout his career, Michael Hahn has collaborated with leading organizations, including Bayer Pharma and Bayer Intellectual Property GmbH. His work in these prominent companies has allowed him to focus on innovative research and development in the pharmaceutical industry.

Collaborations: In his professional journey, Michael has worked alongside esteemed colleagues such as Johannes-Peter Stasch and Frank Wunder. These collaborations have undoubtedly fostered an environment of innovation, enhancing the potential for impactful discoveries in the field of medicine.

Conclusion: Michael Hahn has established himself as a significant innovator in the pharmaceutical sector with his substantial contributions toward treating respiratory and cardiopulmonary disorders. His ongoing research and patent developments continue to push the boundaries of medical science, ultimately improving patient outcomes.

This text is generated by artificial intelligence and may not be accurate.